Literature DB >> 30517710

Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study.

Pierluigi Macchioni1, Luigi Boiardi1, Francesco Muratore2, Giovanna Restuccia1, Alberto Cavazza1, Nicolò Pipitone1, Mariagrazia Catanoso1, Pamela Mancuso3, Ferdinando Luberto3, Paolo Giorgi Rossi3, Carlo Salvarani2.   

Abstract

OBJECTIVE: To evaluate the influence of disease-related findings and treatment outcomes on survival in a population-based cohort of Northern Italian patients with GCA.
METHODS: A total of 281 patients with incident temporal artery biopsy (TAB)-proven GCA, diagnosed over a 26-year period (1986-2012) and living in the Reggio Emilia area, were retrospectively evaluated. We analysed clinical, imaging and laboratory findings at diagnosis, pathological patterns of TAB, CS treatment and therapeutic outcomes, and traditional cardiovascular risk factors as factors predictive of survival.
RESULTS: Univariate analysis showed that increased mortality was associated with large vessel involvement at diagnosis [hazard ratio (HR) 5.84], while reduced mortality was associated with female sex (HR 0.66), PMR (HR 0.54), higher haemoglobin levels (HR 0.84) at diagnosis, long-term remission (HR 0.47) and inflammation limited to adventitia or to the adventitial vasa vasorum (HR 0.48) at TAB examination. Multivariate analysis confirmed the association between increased mortality and large vessel involvement (HR 5.14) at diagnosis, between reduced mortality and PMR (HR 0.57) at diagnosis and adventitial inflammation (HR 0.31) at TAB.
CONCLUSION: PMR at diagnosis and inflammation limited to the adventitia at TAB appear to identify subsets of patients with more benign disease, while large vessel involvement at diagnosis is associated with reduced survival.
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  GCA; mortality; survival predictors; temporal artery biopsy

Mesh:

Year:  2019        PMID: 30517710     DOI: 10.1093/rheumatology/key325

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

Review 1.  Large-vessel vasculitis.

Authors:  Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun
Journal:  Nat Rev Dis Primers       Date:  2022-01-06       Impact factor: 65.038

2.  Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients.

Authors:  Francesca Regola; Elisabetta Cerudelli; Giovanni Bosio; Laura Andreoli; Angela Tincani; Franco Franceschini; Paola Toniati
Journal:  Rheumatol Adv Pract       Date:  2020-05-15

3.  Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study.

Authors:  Luca Quartuccio; Miriam Isola; Dario Bruno; Elena Treppo; Laura Gigante; Francesca Angelotti; Riccardo Capecchi; Gianfranco Vitiello; Elena Cavallaro; Antonio Tavoni; Silvia Laura Bosello; Daniele Cammelli; Salvatore De Vita; Elisa Gremese
Journal:  J Transl Autoimmun       Date:  2020-11-28

4.  Survival and death causes of patients with giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.

Authors:  L K Brekke; B-T S Fevang; A P Diamantopoulos; J Assmus; E Esperø; C G Gjesdal
Journal:  Arthritis Res Ther       Date:  2019-06-25       Impact factor: 5.156

5.  Large-vessel involvement is predictive of multiple relapses in giant cell arteritis.

Authors:  Donatienne de Mornac; Olivier Espitia; Antoine Néel; Jérôme Connault; Agathe Masseau; Alexandra Espitia-Thibault; Mathieu Artifoni; Aurélie Achille; Anaïs Wahbi; Mathieu Lacou; Cécile Durant; Pierre Pottier; François Perrin; Julie Graveleau; Mohamed Hamidou; Jean-Benoit Hardouin; Christian Agard
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-05-18       Impact factor: 5.346

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.